Sandbox/v31: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
mNo edit summary
Line 1: Line 1:
__NOEDITSECTION____NOTOC__
__NOEDITSECTION____NOTOC__
{{Meningitis}}
{{Meningitis}}
Line 21: Line 22:
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Newborn, Age <1 Week}}''
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | {{fontcolor|#1F4099|Newborn, Age <1 Week}}
|-
|-
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
Line 44: Line 45:
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Newborn, Age 1—4 Weeks}}''
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | {{fontcolor|#1F4099|Newborn, Age 1—4 Weeks}}
|-
|-
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
Line 67: Line 68:
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Infant & Children}}''
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | {{fontcolor|#1F4099|Infant & Children}}
|-
|-
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
Line 83: Line 84:
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Adult, Age <50 Years}}''
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | {{fontcolor|#1F4099|Adult, Age <50 Years}}
|-
|-
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
Line 101: Line 102:
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Adult, Age >50 Years}}''
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | {{fontcolor|#1F4099|Adult, Age >50 Years}}
|-
|-
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
Line 121: Line 122:
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Immunocompromised}}''
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | {{fontcolor|#1F4099|Immunocompromised}}
|-
|-
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
Line 141: Line 142:
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Recurrent}}''
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | {{fontcolor|#1F4099|Recurrent}}
|-
|-
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
Line 164: Line 165:
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Basilar Skull Fracture}}''
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | {{fontcolor|#1F4099|Basilar Skull Fracture}}
|-
|-
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
Line 179: Line 180:
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
{| style="margin: 0 0 0em 0em; border: 0px; float: left; cellpadding=0; cellspacing= 0; width: 32em;"
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#1F4099|Head Trauma; Post-Neurosurgery}}''
! style="padding: 0 5px; border: 0px; font-size: 100%; background: #F8F8FF" align=center | {{fontcolor|#1F4099|Head Trauma; Post-Neurosurgery}}
|-! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-! style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-

Revision as of 04:43, 20 January 2014


Meningitis Main Page

Patient Information

Overview

Causes

Classification

Viral Meningitis
Bacterial Meningitis
Fungal Meningitis

Differential Diagnosis

Diagnosis

Treatment

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2], Sheng Shi, M.D. [3]

Empiric Therapy Adapted from Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):1693-702.[1]

Community-Acquired Meningitis

 ▸   Newborn, Age <1 Week
 ▸   Newborn, Age 1—4 Weeks
 ▸   Infant & Children
 ▸   Adult, Age <50 Years
 ▸   Adult, Age >50 Years
 ▸   Immunocompromised
 ▸   Recurrent
Newborn, Age <1 Week
Preferred Regimen
Ampicillin 50 mg/kg IV q8h
PLUS
Cefotaxime 100—150 mg/kg/day IV q8—12h
Alternative Regimen
Ampicillin 50 mg/kg IV q8h
PLUS
Gentamicin 2.5 mg/kg IV q12h
Newborn, Age 1—4 Weeks
Preferred Regimen
Ampicillin 200 mg/kg/day IV q6—8h
PLUS
Cefotaxime 150—200 mg/kg/day IV q6—8h
Alternative Regimen
Ampicillin 200 mg/kg/day IV q6—8h
PLUS
Gentamicin 2.5 mg/kg IV q8h
OR
Tobramycin2.5 mg/kg IV q8h
OR
Amikacin 10 mg/kg IV q8h
Infant & Children
Preferred Regimen
Vancomycin 15 mg/kg IV q6h
to achieve serum trough concentrations of 15–20 μg/mL
PLUS
Cefotaxime 225—300 mg/kg/day IV q6–8h
OR
Ceftriaxone 80—100 mg/kg/day IV q12–24h
Adult, Age <50 Years
Preferred Regimen
Vancomycin 30–60 mg/kg/day IV q8–12h
to achieve serum trough concentrations of 15–20 μg/mL
PLUS
Cefotaxime 8–12 g/day IV q4–6h
OR
Ceftriaxone 2 g IV q12h
Add Ampicillin 2 g IV q4h (50 mg/kg IV q6h for children) if meningitis caused by Listeria monocytogenes is also suspected.
Adult, Age >50 Years
Preferred Regimen
Vancomycin 30–60 mg/kg/day IV q8–12h
PLUS
Ampicillin 2 g IV q4h
PLUS
Cefotaxime 8–12 g/day IV q4–6h
OR
Ceftriaxone 2 g IV q12h
Immunocompromised
Preferred Regimen
Vancomycin 30–60 mg/kg/day IV q8–12h
PLUS
Ampicillin 2 g IV q4h
PLUS
Cefepime 2 g IV q8h
OR
Meropenem 2 g IV q8h
Recurrent
Preferred Regimen
Vancomycin 30—60 mg/kg/day IV q8–12h
PLUS
Cefotaxime 8–12 g/day IV q4–6h
OR
Ceftriaxone 2 g IV q12h

Healthcare-Associated Meningitis

 ▸   Basilar Skull Fracture
 ▸   Head Trauma; Post-Neurosurgery
Basilar Skull Fracture
Preferred Regimen
Vancomycin 30—60 mg/kg/day IV q8–12h
PLUS
Cefotaxime 8–12 g/day IV q4–6h
OR
Ceftriaxone 2 g IV q12h
Head Trauma; Post-Neurosurgery
Vancomycin 30—60 mg/kg/day IV q8–12h
PLUS
Ceftazidime 2 g IV q8 h
OR
Cefepime 2 g IV q8h
OR
Meropenem 2 g IV q8h

References

  1. van de Beek, D.; Brouwer, MC.; Thwaites, GE.; Tunkel, AR. (2012). "Advances in treatment of bacterial meningitis". Lancet. 380 (9854): 1693–702. doi:10.1016/S0140-6736(12)61186-6. PMID 23141618. Unknown parameter |month= ignored (help)